Perceptive Discovery Launches Astatine-211 Study Capabilities in the US and UK

PartnershipPositive

AI Analysis

Summary

Perceptive Discovery announced it has launched Astatine-211 study capabilities in the US and UK, becoming the first US provider able to support At-211 studies through its collaboration with Atley Solutions. The expansion broadens access to specialized radiopharmaceutical development infrastructure.

Outcome Details

Perceptive Discovery becomes the first US provider able to support At-211 studies through its collaboration with Atley Solutions

Importance:3/10

Sentiment:

0.30

radiopharmaceuticalastatine-211At-211CROpreclinical servicescollaborationtargeted alpha therapy

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on October 16, 2026 10:04 AM

Read Original